Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313405733> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4313405733 endingPage "66.14" @default.
- W4313405733 startingPage "66.14" @default.
- W4313405733 abstract "Abstract Markers of immune related adverse events and response in patients treated with immune checkpoint inhibitors (ICI) may shed light into ICI resistance, T cell exhaustion and other combinatorial therapies. The elevated levels of these biomarkers have potential to predict if PD-1 or PD-1/CTLA-4 antagonist combination will be effective in a certain Melanoma patient. Therefore, it may potentially guide healthcare providers to change treatment plans. In this study, the ICI treatments we focused on were PD-1 or combination of PD-1/CTLA-4 blockades. The measurement of the biomarkers was conducted at Mayo Clinic, from serum samples obtained in 2 time points, pre-treatments and 2–3 months after the first ICI treatments. Validated IVD kits were used per manufacture’s instruction. Biomarkers could be measured using stored frozen serum samples according to the instructions on how the biomarkers will be measured. We investigated 13 biomarkers in the sera of 76 melanoma patients who received immune checkpoint therapies. The biomarkers tested were, Human ELAFIN ELISA, Human IL-18 ELISA, Reg3α + Universal kit, Anti-Nuclear Antibody Test System, FLUORO AID-1 Test for anti-mitochondrial antibodies, anti-smooth muscle antibodies and anti-parietal cell antibodies, Anti-MDA5 ELISA Kit, Anti-synthetase ELISA Skin, Antineutrophil cytoplasmic antibodies MPO-ANCA ELISA, Antineutrophil cytoplasmic antibodies PR3-ANCA ELISA, Dsg1, Dsg3 ELISA, BP180, BP230, type-VII collagen. When compared with the samples obtained before treatments, IL-18 levels significantly elevated (p value < 0.0001) in post treatment samples of non-responders. Further studies are needed to confirm if elevated IL-18 contribute to the biology of resistance to ICI therapies. Supported by MBLI" @default.
- W4313405733 created "2023-01-06" @default.
- W4313405733 creator A5011627735 @default.
- W4313405733 creator A5014320938 @default.
- W4313405733 creator A5027176998 @default.
- W4313405733 creator A5031005364 @default.
- W4313405733 creator A5075680219 @default.
- W4313405733 creator A5087651357 @default.
- W4313405733 date "2022-05-01" @default.
- W4313405733 modified "2023-09-23" @default.
- W4313405733 title "Analysis of biomarkers in melanoma patients receiving ICI treatments: pre- vs post in responders and progressors" @default.
- W4313405733 doi "https://doi.org/10.4049/jimmunol.208.supp.66.14" @default.
- W4313405733 hasPublicationYear "2022" @default.
- W4313405733 type Work @default.
- W4313405733 citedByCount "0" @default.
- W4313405733 crossrefType "journal-article" @default.
- W4313405733 hasAuthorship W4313405733A5011627735 @default.
- W4313405733 hasAuthorship W4313405733A5014320938 @default.
- W4313405733 hasAuthorship W4313405733A5027176998 @default.
- W4313405733 hasAuthorship W4313405733A5031005364 @default.
- W4313405733 hasAuthorship W4313405733A5075680219 @default.
- W4313405733 hasAuthorship W4313405733A5087651357 @default.
- W4313405733 hasConcept C126322002 @default.
- W4313405733 hasConcept C159654299 @default.
- W4313405733 hasConcept C185592680 @default.
- W4313405733 hasConcept C197934379 @default.
- W4313405733 hasConcept C203014093 @default.
- W4313405733 hasConcept C2776088058 @default.
- W4313405733 hasConcept C2777658100 @default.
- W4313405733 hasConcept C2777701055 @default.
- W4313405733 hasConcept C2780030458 @default.
- W4313405733 hasConcept C2781197716 @default.
- W4313405733 hasConcept C502942594 @default.
- W4313405733 hasConcept C55493867 @default.
- W4313405733 hasConcept C71924100 @default.
- W4313405733 hasConcept C8891405 @default.
- W4313405733 hasConcept C90924648 @default.
- W4313405733 hasConceptScore W4313405733C126322002 @default.
- W4313405733 hasConceptScore W4313405733C159654299 @default.
- W4313405733 hasConceptScore W4313405733C185592680 @default.
- W4313405733 hasConceptScore W4313405733C197934379 @default.
- W4313405733 hasConceptScore W4313405733C203014093 @default.
- W4313405733 hasConceptScore W4313405733C2776088058 @default.
- W4313405733 hasConceptScore W4313405733C2777658100 @default.
- W4313405733 hasConceptScore W4313405733C2777701055 @default.
- W4313405733 hasConceptScore W4313405733C2780030458 @default.
- W4313405733 hasConceptScore W4313405733C2781197716 @default.
- W4313405733 hasConceptScore W4313405733C502942594 @default.
- W4313405733 hasConceptScore W4313405733C55493867 @default.
- W4313405733 hasConceptScore W4313405733C71924100 @default.
- W4313405733 hasConceptScore W4313405733C8891405 @default.
- W4313405733 hasConceptScore W4313405733C90924648 @default.
- W4313405733 hasIssue "1_Supplement" @default.
- W4313405733 hasLocation W43134057331 @default.
- W4313405733 hasOpenAccess W4313405733 @default.
- W4313405733 hasPrimaryLocation W43134057331 @default.
- W4313405733 hasRelatedWork W1485688150 @default.
- W4313405733 hasRelatedWork W1582278270 @default.
- W4313405733 hasRelatedWork W2262554279 @default.
- W4313405733 hasRelatedWork W2752773766 @default.
- W4313405733 hasRelatedWork W2900818500 @default.
- W4313405733 hasRelatedWork W2955428297 @default.
- W4313405733 hasRelatedWork W2963333658 @default.
- W4313405733 hasRelatedWork W2969687411 @default.
- W4313405733 hasRelatedWork W2981372661 @default.
- W4313405733 hasRelatedWork W4382344122 @default.
- W4313405733 hasVolume "208" @default.
- W4313405733 isParatext "false" @default.
- W4313405733 isRetracted "false" @default.
- W4313405733 workType "article" @default.